Amarin Corporation PLC
431 articles with Amarin Corporation PLC
-
JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level
2/24/2022
JAMA Network Open has published “Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment,”1 which evaluated the more than 8,000 patients recruited to participate in the REDUCE-IT® clinical trial.
-
Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022
2/15/2022
Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022 at 8:00 a.m. ET.
-
Amarin Provides Preliminary 2021 Revenue and Outlook for 2022
1/10/2022
Amarin Corporation plc provided a business update, including preliminary unaudited full-year 2021 revenue results.
-
Amarin to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Amarin Corporation plc is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 am ET.
-
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
-
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021
11/16/2021
Amarin Corporation plc (NASDAQ:AMRN) today reported an overview of new data relating to VASCEPA®/VAZKEPA (icosapent ethyl) presented at the American Heart Association (AHA) Scientific Sessions 2021, which took place virtually from November 13-15, 2021.
-
Amarin Reports Subgroup Data from REDUCE-IT® Highlighting Benefits of VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease Presented in Rapid Fire Oral Session Presentation at the AHA Scientific Sessions 2021
11/15/2021
Amarin Corporation plc announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA in patients with prior peripheral artery disease at risk for major adverse cardiovascular events were delivered in a Rapid Fire Oral Session Presentation at the American Heart Association Scientific Sessions 2021, which took place virtually from November 13-15, 2021.
-
Amarin to Present at Two Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
Amarin Corporation plc announced that Karim Mikhail, president and chief executive officer of Amarin, and Michael Kalb, chief financial officer of Amarin, are scheduled to participate in the following upcoming investor conferences.
-
Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update
11/3/2021
Amarin Corporation plc, announced financial results for the third quarter and nine months ended September 30, 2021 and provided an update on Company operations.
-
Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
10/20/2021
Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarin’s senior management team to discuss the Company's third quarter 2021 financial results on Wednesday, November 3, 2021, at 7:30 a.m. ET.
-
There are roughly 750 sales representatives for Amarin at present, which the company intends to whittle down to 300 as it adopts a more digital approach to marketing.
-
Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement
9/22/2021
Amarin Corporation plc outlined its new Go-to-Market strategy to accelerate growth of VASCEPA® in the United States, which focuses on expanding healthcare professional engagement through a new omnichannel platform, enhancing managed care access and optimizing VASCEPA prescriptions for cardiovascular risk reduction.
-
Amarin to Participate in September 2021 Investment Conferences
9/13/2021
Amarin Corporation plc announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021.
-
Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany
9/13/2021
Amarin Corporation plc (NASDAQ:AMRN) today announced the first European launch of VAZKEPA (icosapent ethyl) in Germany. VAZKEPA received marketing authorization from the European Commission in March 2021 and the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain in April 2021.
-
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology
8/31/2021
Amarin Corporation plc reported an overview of new data relating to VASCEPA®/VAZKEPA presented at ESC Congress 2021, organized by the European Society of Cardiology, taking place virtually from August 27 – August 30, 2021.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the ESC
8/23/2021
Amarin Corporation plc announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA in patients with prior heart attack, known as myocardial infarction, at risk for major adverse cardiovascular events were delivered in a Late Breaking Science Presentation at ESC Congress 2021, organized by the European Society of Cardiology, taking place virtually from August 27 – August 30, 2021.
-
Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021
8/16/2021
Amarin Corporation plc today announced that new data that add to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients at risk for major adverse cardiovascular events will be presented at ESC Congress 2021, organized by the European Society of Cardiology (ESC), being held virtually from August 27 – August 30, 2021.
-
Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update
8/5/2021
Amarin Corporation plc, announced financial results for the second quarter and six months ended June 30, 2021 and provided an update on company operations.
-
Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021
7/15/2021
Amarin Corporation plc announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter and six month 2021 financial results and provide an operational update on Thursday, August 5, 2021, at 7:30 a.m. ET.